Bristol-Myers Squibb Gets FDA Approval for Opdivo-Yervoy Combo in Liver Cancer Treatment

MT Newswires Live2025-04-12

Bristol-Myers Squibb (BMY) received the US Food and Drug Administration's full approval for Opdivo plus Yervoy as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma, a form of liver cancer.

The approval was supported by results from a phase 3 trial, which demonstrated that the combination therapy significantly improved overall survival to 23.7 months, compared with 20.6 months with lenvatinib or sorafenib, reducing the risk of death by 21%, the company said Friday in a statement.

The trial's safety analysis involved 657 patients with 332 receiving Opdivo plus Yervoy, and 53% of those patients experienced serious adverse reactions, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • setia100
    2025-04-12
    setia100
    The drug will squeeze the patients addiction 4 months ❗😰
Leave a comment
1
1